| Literature DB >> 33198359 |
Beatriz Ostos-Díaz1, María Jesús Casuso-Holgado2, María Jesús Muñoz-Fernández1, Ana F Carazo3, Rocío Martín-Valero4, Esther M Medrano-Sánchez2.
Abstract
The primary purpose of this research was to investigate the feasibility and safety of delivering an early supervised physical therapy intervention to women after sentinel lymph node biopsy (SLNB); furthermore, we aimed to provide explorative data on its effects. This was a single-site feasibility study. Pre- and post-evaluation was conducted from baseline to follow-up at 6 months. Primary outcomes were participant recruitment, participant retention, compliance with the intervention, and safety. Secondary outcomes were shoulder range of motion, handgrip strength, upper limb pain and disability, scar recovery, quality of life, and the incidence of axillary web syndrome (AWS) and/or lymphoedema. A total of 43 participants (mean age 55.37 years) completed the trial and the follow-up period. A total of 91% of women who met the inclusion criteria agreed to participate, and the adherence rate was 80%. No adverse events were reported. Incidence of AWS was 9.3%, and there was no incidence of lymphoedema at 6 months. Our results support that this intervention is feasible and safe. The results presented in this study also provide preliminary evidence for the use of a rehabilitation program as a supportive intervention after SLNB, but future research on effectiveness is needed.Entities:
Keywords: breast neoplasm; health education; physical therapy specialty; rehabilitation; sentinel lymph node biopsy
Mesh:
Year: 2020 PMID: 33198359 PMCID: PMC7697742 DOI: 10.3390/ijerph17228382
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Temporal distribution of program sessions.
Figure 2Stretching exercises in the scar recovery phase.
Figure 3Patient flow chart.
Subjects´ demographics and clinical-surgical characteristics.
| Demographics and Characteristics | Number of Subjects = 43 |
|---|---|
|
| Mean ± SD: 55.37 ±10.7 |
| <45 | 7 (16.28%) |
| 45–54 | 13 (30.23%) |
| 55–64 | 11 (25.58%) |
| +65 | 12 (27.90%) |
|
| Mean ± SD: 27.14 ± 6.08 |
| Normal: 18.5−24.9 | 15 (35.71%) |
| Overweight: 25–29.9 | 17 (40.47%) |
| Obese: ≥ 30 | 10 (23.80%) |
|
| |
| Caucasian | 40 (93%) |
| African | 1 (2.3%) |
| Latin American | 2 (4.7%) |
|
| |
| Ductal carcinoma in situ (DCIS) | 6 (14%) |
| Invasive Ductal Carcinoma (IDC) | 36 (83.7%) |
| Lobular carcinoma in situ | 1 (2.3%) |
|
| |
| 0 | 6 (15.8%) |
| IA | 23 (60.5%) |
| IIA | 4 (10.5%) |
| IB | 2 (5.3%) |
| IIB | 3 (7.9%) |
|
| |
| Simple unilateral mastectomy | 6 (14%) |
| Breast conserving surgery | 37 (86%) |
|
| Mean ± SD: 2.19 ± 1.18 |
|
| |
| Yes | 6 (14%) |
| No | 37 (86%) |
|
| |
| Right | 23 (53.5%) |
| Left | 19 (44.2%) |
| Bilateral | 1 (2.3%) |
|
| |
| Ipsilateral side | 24 (55.8%) |
| Contralateral side | 19 (44.2%) |
|
| |
| Yes | 13 (30.2%) |
| No | 30 (69.8%) |
|
| |
| Radiation | 2 (4.7%) |
| Chemotherapy | 10 (23.3%) |
|
| Numbers of subjects = 13 (30.23) |
|
| Mean ±SD: 9.38 ± 4.50 |
|
| Mean ± SD: 23.16 ± 5.15 |
|
| Mean ± SD: 4.09 ±0.366 |
Figure 4Outcome graphical representation in boxplots: (a) range of motion, (b) handgrip strength, (c) shoulder pain, (d) shoulder disability, (e) state of scar, and (f) myofascial adhesions. Effect size (r).
Outcome measures for participants at baseline, post-surgery, and post-intervention.
| Outcomes | T0 | T1 | T2 | T1-T0 | T2-T1 | T2-T0 | |
|---|---|---|---|---|---|---|---|
| Global shoulder ROM (% index) | 96.81 ± 8.13 | 87.95 ± 13.54 | 99.76 ± 1.56 | ||||
| Grip strength (Kg) | 12.48 ± 5.11 | 14.36 ± 5 | 16.56 ± 4.71 | ||||
| Shoulder pain (SPADI 0–50 points) | 8.27 ± 11.86 | 13.23 ± 10.27 | 8.58 ± 8.23 | 0.678 | |||
| Shoulder disability (SPADI 0–80 points) | 7.09 ± 12.43 | 21.97 ± 19.41 | 7.69 ± 12.45 | 0.519 | |||
| Global EORTC QLQ-BR23 function | 54.89 ± 16.75 | 52.29 ± 15.35 | 52.92 ± 16.22 | 0.380 | 0.761 | 0.601 | |
| Global EORTC QLQ-BR23 symptoms | 14.32 ± 16.55 | 20.40 ± 12.83 | 18.64 ± 11.80 | 0.223 | 0.14 | ||
| State of scar (POSAS 0–60 points) | 24.74 ± 10.15 | 9.53 ± 6.19 | - | - | |||
| Myofascial adhesions (MAP-BC 0–63 points) | 24.74 ± 10.37 | 5.62 ± 5.86 | - | - | |||
| Axillary web syndrome (%) | Yes | 4(9.3) | - | - | - | ||
| No | 39(90.7) | - | - | - | |||
| Lymphedema (%) | Yes | None | - | - | - | ||
| No | 43 (100) | - | - | - | |||
SD: standard deviation; med [min-max]: median [minimum-maximum]; T0: baseline, T1: post-surgery, T2: post-intervention; ↑ EORTC QLQ-BR23 functioning scales, higher scores indicate better functioning.; ↓ EORTC QLQ-BR23 symptoms scales, higher scores indicate more problems. MAP-BC: Myofascial Adhesions in Patients after Breast Cancer tool, POSAS: Patient and Observer Scar Assessment Scale, SPADI: Shoulder Pain and Disability Index. Bold text indicates significant differences.